Frankfurt
26.03.25
08:05 Uhr
0,171 Euro
-0,008
-4,47 %
-4,47 %
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 27.02. | AlzeCure Pharma: AlzeCure Publishes its Year-End Report for January - December 2024 | 565 | ACCESS Newswire | STOCKHOLM, SWEDEN / ACCESS Newswire / February 27, 2025 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR) today announced that its Year-end report for the period January... ► Artikel lesen | |
| 24.02. | AlzeCure Pharma: New Article Showing the Unique Mechanism of Action Behind Alzstatin as an Alzheimer's Treatment | 211 | ACCESS Newswire | STOCKHOLM, SWEDEN / ACCESS Newswire / February 24, 2025 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR) ), a pharmaceutical company that develops candidate drugs for... ► Artikel lesen | |
| 17.02. | AlzeCure Pharma: AlzeCure Receives EU Grant for Phase 2 Clinical Trial of NeuroRestore ACD856 for Alzheimer's Disease | 250 | ACCESS Newswire | STOCKHOLM, SWEDEN / ACCESS Newswire / February 17, 2025 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for... ► Artikel lesen | |
| 21.01. | AlzeCure's NeuroRestore ACD856 to be presented at AD/PD 2025 | 2 | PharmaTimes | ||
| ALZECURE PHARMA Aktie jetzt für 0€ handeln | |||||
| 21.01. | AlzeCure Pharma: AlzeCure Receives Abstract Acceptance at Alzheimer's Congress AD/PD 2025 on NeuroRestore ACD856 | 308 | ACCESS Newswire | STOCKHOLM, SE / ACCESSWIRE / January 21, 2025 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops candidate drugs for diseases... ► Artikel lesen | |
| 27.11.24 | AlzeCure Pharma: AlzeCure to Present at the Pharma Outsourcing Conference in Stockholm | 312 | ACCESS Newswire | STOCKHOLM, SWEDEN / ACCESSWIRE / November 27, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops small molecule drugs for... ► Artikel lesen | |
| 26.11.24 | AlzeCure Pharma to Present at Redeye Life Science Day on December 3 | 276 | ACCESS Newswire | STOCKHOLM, SWEDEN / ACCESSWIRE / November 26, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops candidate drugs for diseases... ► Artikel lesen | |
| 20.11.24 | AlzeCure Pharma to Present at Stora Aktiedagarna in Stockholm | 382 | ACCESS Newswire | STOCKHOLM, SWEDEN / ACCESSWIRE / November 20, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops candidate drugs for diseases... ► Artikel lesen | |
| 11.11.24 | AlzeCure Pharma: AlzeCure Publishes its Interim Report for January - September 2024 | 698 | ACCESS Newswire | STOCKHOLM, SE / ACCESSWIRE / November 11, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR) today announced that its interim report for the period January - September... ► Artikel lesen | |
| 30.10.24 | AlzeCure Pharma: AlzeCure Presents New Anti-Inflammatory Data with NeuroRestore ACD856 at the Alzheimer's Conference CTAD | 462 | ACCESS Newswire | STOCKHOLM, SE / ACCESSWIRE / October 30, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting... ► Artikel lesen | |
| 28.10.24 | AlzeCure Pharma: AlzeCure Presents New Positive Data for the TrkA-NAM Pain Project Against Osteoarthritis | 266 | ACCESS Newswire | STOCKHOLM, SE / ACCESSWIRE / October 28, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for CNS diseases... ► Artikel lesen | |
| 24.10.24 | AlzeCure Pharma: AlzeCure to Present at the International Partnering Conference Bioscience 2024 on November 7 | 357 | ACCESS Newswire | STOCKHOLM, SE / ACCESSWIRE / October 24, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops candidate drugs for diseases... ► Artikel lesen | |
| 17.10.24 | AlzeCure Pharma's CEO Martin Jönsson to present at Redeye's Neurology Day | 270 | ACCESS Newswire | STOCKHOLM, SE / ACCESSWIRE / October 17, 2024 / AlzeCure Pharma (STO:ALZCUR) (FRA:AC6) AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops candidate drugs for diseases... ► Artikel lesen | |
| 10.10.24 | AlzeCure Pharma Broadcasts Live Event About the Phase II Candidate ACD440 Against Neuropathic Pain | 310 | ACCESS Newswire | STOCKHOLM, SE / ACCESSWIRE / October 10, 2024 / AlzeCure Pharma (STO:ALZCUR) (FRA:AC6) AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops candidate drugs for diseases... ► Artikel lesen | |
| 02.10.24 | AlzeCure's abstract on ACD856's effects to be presented at Alzheimer's conference | 5 | PharmaTimes | ||
| 01.10.24 | AlzeCure Pharma: AlzeCure's Abstract on ACD856's Anti-inflammatory Effects to be Presented at a Leading Alzheimer's Conference | 311 | ACCESS Newswire | STOCKHOLM, SWEDEN / ACCESSWIRE / October 1, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases... ► Artikel lesen | |
| 26.08.24 | AlzeCure Pharma: AlzeCure Publishes its Interim Report for January - June 2024 | 527 | ACCESS Newswire | STOCKHOLM, SE / ACCESSWIRE / August 26, 2024 / AlzeCure Pharma (STO:ALZCUR) (FRA:AC6) AlzeCure Pharma AB (publ) (FN STO: ALZCUR) today announced that its interim report for the period January - June... ► Artikel lesen | |
| 13.08.24 | AlzeCure Pharma: New Scientific Article on NeuroRestore ACD856 and its Improved Cognition and Disease Modification of Alzheimer's Disease | 753 | ACCESS Newswire | STOCKHOLM, SE / ACCESSWIRE / August 13, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting... ► Artikel lesen | |
| 07.08.24 | AlzeCure Pharma: New Results from AlzeCure's Pain Project TrkA-NAM Presented at the Pain Conference IASP 2024 | 319 | ACCESS Newswire | STOCKHOLM, SE / ACCESSWIRE / August 07, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting... ► Artikel lesen | |
| 13.06.24 | AlzeCure Pharma: New Scientific Article Published on Positive Clinical Results with Painless ACD440 Against Neuropathic Pain | 419 | ACCESS Newswire | STOCKHOLM, SWEDEN / ACCESSWIRE / June 13, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases... ► Artikel lesen |
Seite:
1 2 Weiter >>
30 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VERTEX PHARMACEUTICALS | 472,75 | +0,27 % | Jim Cramer on Vertex (VRTX): "A Revolutionary Anti-Pain Drug" | ||
| VIATRIS | 8,348 | +0,26 % | Kurs von Viatris fällt ab (8,43462 €) | Die Aktie von Viatris notiert heute etwas leichter. Zuletzt zahlten Investoren für das Wertpapier 9,16 US-Dollar. Ein Minus von 1,56 Prozent steht gegenwärtig für der Anteilsschein von Viatris zu Buche.... ► Artikel lesen | |
| OPKO HEALTH | 1,682 | +1,14 % | OPKO HEALTH, INC. - 10-K/A, Annual Report | ||
| JAGUAR HEALTH | 5,725 | -5,22 % | XFRA CAPITAL ADJUSTMENT INFORMATION - 21.03.2025 | Das Instrument 2UH US00183L1026 ANGI INC DL-,001 EQUITY wird cum Kapitalmassnahme gehandelt am 21.03.2025 und ex Kapitalmassnahme am 24.03.2025 The instrument 2UH US00183L1026 ANGI INC DL-,001 EQUITY... ► Artikel lesen | |
| ALTIMMUNE | 5,447 | +0,46 % | Altimmune, Inc: Altimmune Added to Nasdaq Biotechnology Index | GAITHERSBURG, Md., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will be added to the Nasdaq Biotechnology Index... ► Artikel lesen | |
| SELLAS LIFE SCIENCES | 1,156 | +0,87 % | SELLAS Life Sciences Group, Inc.: SELLAS Life Sciences Reports Full Year 2024 Financial Results and Provides Corporate Update | - Announced Positive Outcome of Interim Analysis for its Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) with Next and Final Analysis Planned Upon Reaching 80 Events... ► Artikel lesen | |
| AURINIA PHARMACEUTICALS | 7,922 | -1,34 % | Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2024 Financial and Operational Results, Announces Strategic Restructuring to Sharpen Focus on Continued LUPKYNIS Growth and AUR200 Development | ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today issued its financial results for the third quarter and nine months... ► Artikel lesen | |
| KIORA PHARMACEUTICALS | 3,050 | 0,00 % | Kiora Pharmaceuticals, Inc.: Kiora Pharmaceuticals Reports 2024 Results; Retinal Disease Drug Development Pipeline Continues to Advance; Cash and Short-Term Investments Expected to Fund Operations into 2027 | Encinitas, California--(Newsfile Corp. - March 25, 2025) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced its 2024 financial results and provided an update on... ► Artikel lesen | |
| PHOTOCURE | 5,060 | +3,90 % | Photocure appoints Jane Healy as Vice President and General Manager EMEA | OSLO, Norway, March 26, 2025 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, today announced the appointment of Jane Healy as Vice President and General Manager EMEA.
Ms.... ► Artikel lesen | |
| LIPOCINE | 3,510 | 0,00 % | Lipocine Inc.: Lipocine Announces Financial Results for the Full Year Ended December 31, 2024 | SALT LAKE CITY, March 13, 2025 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment... ► Artikel lesen | |
| ACLARIS THERAPEUTICS | 1,646 | +10,62 % | Aclaris Therapeutics Aktie: Frische Impulse sorgen für Bewegung! | Die Aclaris Therapeutics Aktie verzeichnet derzeit eine bemerkenswerte Entwicklung am Markt. Nach einem monatlichen Rückgang von 11,98% hat sich der Kurs aktuell bei 1,69 EUR (Stand: 08. März 2025)... ► Artikel lesen | |
| EUROBIO SCIENTIFIC | 25,350 | 0,00 % | Biovica International: Biovica Signs Agreement With Eurobio Scientific Covering 60 Percent of European Market | UPPSALA, SE / ACCESS Newswire / March 5, 2025 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) Biovica, active in cancer monitoring, has signed a collaboration agreement with Eurobio Scientific... ► Artikel lesen | |
| MEDICURE | 0,410 | 0,00 % | Medicure, Inc.: Medicure Announces Closing of Purchase Agreement for the Acquisition of Gateway Medical Pharmacy | WINNIPEG, MB / ACCESS Newswire / March 11, 2025 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC PINK:MCUJF), a company focused on the development and commercialization of pharmaceuticals... ► Artikel lesen | |
| BAYER | 23,075 | -2,10 % | Bayer AG Aktie: Innovationen auf Erfolgskurs! | Die Bayer-Aktie verzeichnete am Dienstag einen bemerkenswerten Kursanstieg von 4,5 Prozent und kletterte auf 24,86 Euro im XETRA-Handel. Dieses positive Momentum reiht sich in einen nachhaltigen Aufwärtstrend... ► Artikel lesen | |
| MERCK KGAA | 127,95 | -2,18 % | Weitere Übernahmen erwartet - Bayer, BioNxt Solutions, Merck KGaA | Die aggressive Zollpolitik der neuen US-Administration mit US-Präsident Trump hat einige Marktteilnehmer verunsichert und sie zu Umschichtungen innerhalb der Portfoliostruktur veranlasst. Europäische... ► Artikel lesen |
ALZECURE PHARMA AB gehört der Branche Pharma an. Der aktuelle Kurs liegt bei 0,171 Euro und damit -4,47 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ALZECURE PHARMA AB finden Sie auf Wallstreet Online.
